This page uses content from Wikipedia and is licensed under CC BY-SA.

Zicronapine

Zicronapine
Zicronapine.svg
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC22H27ClN2
Molar mass354.9 g/mol g·mol−1
3D model (JSmol)

Zicronapine (/zˈkrɒnəpn/ zye-KRON-ə-peen, previously known as Lu 31-130) is an atypical antipsychotic medication formerly under development by H. Lundbeck A/S. In phase II studies zicronapine showed statistically significant separation from placebo and convincing efficacy and safety data when compared to olanzapine.[1]

Zicronapine exhibits monoaminergic activity and has a multi-receptorial profile. In vitro and in vivo it has shown potent antagonistic effects at dopamine D1, D2 and serotonin 5HT2A receptors.[2]

In 2014 Lundbeck removed zicronapine from its development portfolio in favor of pursuing the more promising antipsychotic Lu AF35700 (a prodrug of Lu AF356152).[3]

References

  1. ^ "The clinical phase III programme commenced on zicronapine". January 20, 2011. Retrieved 6 February 2014.
  2. ^ "Zicronapine shows significant positive data in clinical phase II in the treatment of patients with schizophrenia - planning for continued clinical work". December 18, 2009. Retrieved 6 February 2014.
  3. ^ "Performance in 2014 positions Lundbeck well for 2015 and beyond" (PDF). February 5, 2015. Retrieved 18 June 2015.